Entrada Therapeutics Secures MHRA Approval for Duchenne Clinical Trial

Entrada Therapeutics has taken a major step forward in the fight against Duchenne muscular dystrophy (DMD) with MHRA approval to launch ELEVATE-44-201, a Phase 1/2 trial of ENTR-601-44. The study will assess safety, tolerability, and efficacy in patients with exon 44 skipping mutations, aiming to bring much-needed treatment options to those with limited alternatives. Entrada’s CEO, Dipal Doshi, emphasized the urgency of their mission, stating that every moment counts for families affected by this progressive disease.

This trial builds on promising Phase 1 results, where ENTR-601-44 was well tolerated with no serious adverse effects. The upcoming study will follow 24 participants, evaluating multiple dosage levels and tracking improvements in dystrophin production and patient quality of life. With the trial set to begin in Q2 2025, researchers and families alike are hopeful that this next phase will bring a breakthrough in the treatment of Duchenne, providing a new path forward for those impacted by the disease.